IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3730
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$43M
Mark A. Emalfarb
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$DYAI DYADIC INTERNATIONAL INC | 39 | 35 | 41 | 23 | - | - | -230.1% | -51.4% | 63.9% | -215.8% | -220.2% | 201.8% | 0.0% | 348.0x | $43M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
DYADIC INTERNATIONAL INC (DYAI) receives a "Avoid" rating with a composite score of 38.5/100. It ranks #3730 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for DYAI.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 35 | 23 | +12ALPHA |
| MOMENTUM | 23 | 11 | +12ALPHA |
| VALUATION | 41 | 30 | +11ALPHA |
| INVESTMENT | 35 | 60 | -25DRAG |
| STABILITY | 65 | 63 | +2NEUTRAL |
| SHORT INT | 47 | 44 | +3NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -230.1% (sector -1.9%)
GM 64% vs sector 44%, OM -216% vs sector 3%
Capital turnover N/A, R&D intensity 73.1%
Rev growth 202%, 8yr history
Interest coverage -16.9x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate DYADIC INTERNATIONAL INC (DYAI) as Avoid with a composite score of 38.5/100 at a current price of $0.82. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
DYADIC INTERNATIONAL INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 38.5/100 places it at rank #3730 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 64% signal strong pricing power.
Stable competitive position in a defensive sector.
Leverage of 348% D/E amplifies downside risk.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
DYADIC INTERNATIONAL INC represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags DYADIC INTERNATIONAL INC with an Avoid rating, assigning a composite score of 38.5/100 and 1 out of 5 stars. Ranked #3730 of 7,333 stocks, DYAI falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
DYAI's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -230.1% (sector avg: -1.9%), gross margins of 63.9% (sector avg: 44.1%), net margins of -220.2% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 41/100, DYAI appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 11.10x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
DYADIC INTERNATIONAL INC's investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 201.8% vs. a sector average of 6.7% and a return on assets of -51.4% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
DYADIC INTERNATIONAL INC is experiencing notably weak momentum with a score of just 23/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 201.8% year-over-year, while a beta of 0.59 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
DYAI shows good financial stability with a score of 65/100. Key stability metrics include a beta of 0.59 and a debt-to-equity ratio of 348.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 47/100 for DYAI suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 348.00x), micro-cap liquidity risk. With a $43M market cap (micro-cap), DYADIC INTERNATIONAL INC may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
DYADIC INTERNATIONAL INC is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3730 of 7,333 overall (49th percentile). Key comparisons include ROE of -230.1% trailing the -1.9% sector median and operating margins of -215.8% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While DYAI currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (23) would have the largest impact on the composite score.
ROE 12013% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 45% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 8699% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Dyadic International (NASDAQ:DYAI) announced a deficiency notice from Nasdaq for not maintaining the minimum $1 bid price for 30 consecutive business days. The company has 180 calendar days, until June 17, 2026, to regain compliance by having its stock close at $1 or higher for at least 10 consecutive business days. Dyadic plans to monitor its stock price and evaluate options to address this issue, while also continuing collaborations and product offerings despite recent financial challenges including an earnings miss.
Dyadic Applied BioSolutions reported significant commercial and product milestones in Q3 2025, including receiving a $250,000 payment from the Inzymes partnership and achieving a $500,000 productivity milestone for recombinant human albumin. The company is advancing towards commercial launches for several products like albumin, transferrin, and DNase I, with strategic partnerships and internal developments positioning it for revenue growth. These developments underscore Dyadic's transition towards becoming a commercially focused, revenue-driven biotechnology company.
Dyadic International (NASDAQ: DYAI) announced that independent analysis confirmed its animal-free bovine serum albumin is structurally identical to commercial animal albumin, opening new commercialization opportunities. This recombinant alternative, efficiently expressed with high purity using a filamentous fungal strain, is a game-changer for the cultivated meat industry by making it slaughter-free and lowering production costs. It also has significant applications in the pharmaceutical industry, offering a cost-effective and ethical alternative to animal-derived BSA, with the global albumin market projected to reach US$ 8.2 billion by 2028.
JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals (“Proliant”), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announ
Dyadic International's stock has seen a recent rebound after hitting 52-week lows, sparking questions about whether this rally is sustainable for the speculative micro-cap biotech. Despite the uptick, the stock remains deeply discounted from its one-year high, reflecting broader bearish sentiment and a lack of significant catalysts. The company's future hinges on securing high-impact licensing deals or partnerships to validate its biotechnology platform and shift its narrative from a high-risk swing play to a more stable investment.